Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.56 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.56 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.49 |
| ▸ | ANPEP | P15144 | 2/20 | 0.48 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | LAP3 | P28838 | 3/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14541149 | 1.00 | EPHX1 (0.56) | EPHX1CSNK1ESLC15A1ANPEPALPI | |
| SCHEMBL5170196 | 1.00 | EPHX1 (0.56) | EPHX1CSNK1ESLC15A1ANPEPALPI | |
| SCHEMBL14671509 | 1.00 | EPHX1 (0.56) | EPHX1CSNK1ESLC15A1ANPEPALPI | |
| SCHEMBL7983260 | 1.00 | EPHX1 (0.56) | EPHX1CSNK1ESLC15A1ANPEPALPI | |
| SCHEMBL14541480 | 1.00 | EPHX1 (0.56) | EPHX1CSNK1ESLC15A1ANPEPALPI | |
| SCHEMBL996512 | 1.00 | EPHX1 (0.56) | EPHX1CSNK1ESLC15A1ANPEPALPI | |
| Hydrochloric Acid SCHEMBL4977968 | 0.98 | CSNK1E (0.54) | EPHX1CSNK1ESLC15A1ANPEPALPI | |
| Hydrochloric Acid SCHEMBL5168479 | 0.98 | CSNK1E (0.54) | EPHX1CSNK1ESLC15A1ANPEPALPI | |
| Hydrochloric Acid SCHEMBL2232703 | 0.98 | CSNK1E (0.54) | EPHX1CSNK1ESLC15A1ANPEPALPI | |
| Sulfuric Acid SCHEMBL5172847 | 0.91 | CSNK1E (0.49) | EPHX1CSNK1ESLC15A1ANPEPALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528923-B1 | PROCESS FOR THE PREPARATION OF DARUNAVIR AND DARUNAVIR INTERMEDIATES | MAPI PHARMA LTD (IL) | 2014-07-30 | — | — | EP | claimed |
| US-20120296101-A1 | PROCESS FOR THE PREPARATION OF DARUNAVIR AND DARUNAVIR INTERMEDIATES | MAPI PHARMA LIMITED (IL) | 2012-11-22 | — | — | US | claimed |
| US-10544157-B2 | Process for preparation of Darunavir | LAURUS LABS LIMITED (IN) | 2020-01-28 | — | — | US | disclosed |
| US-20190144461-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | LAURUS LABS LIMITED (IN) | 2019-05-16 | — | — | US | disclosed |
| US-20160355525-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | LAURUS LABS LIMITED (IN) | 2016-12-08 | — | — | US | disclosed |
| US-20160355525-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | LAURUS LABS LIMITED (IN) | 2016-12-08 | — | — | US | disclosed |
| US-9475821-B2 | Process for preparation of Darunavir | LAURUS LABS PRIVATE LIMITED (IN) | 2016-10-25 | — | — | US | disclosed |
| US-9475821-B2 | Process for preparation of Darunavir | LAURUS LABS PRIVATE LIMITED (IN) | 2016-10-25 | — | — | US | disclosed |
| US-20150203506-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | LAURUS LABS PRIVATE LTD. (IN) | 2015-07-23 | — | — | US | disclosed |
| US-20150203506-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | LAURUS LABS PRIVATE LTD. (IN) | 2015-07-23 | — | — | US | disclosed |
| US-8835684-B2 | Preparation of 2R,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines | AMPAC FINE CHEMICALS LLC (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120296101-A1 | PROCESS FOR THE PREPARATION OF DARUNAVIR AND DARUNAVIR INTERMEDIATES | MAPI PHARMA LIMITED (IL) | 2012-11-22 | — | — | US | disclosed |
| US-20120296101-A1 | PROCESS FOR THE PREPARATION OF DARUNAVIR AND DARUNAVIR INTERMEDIATES | MAPI PHARMA LIMITED (IL) | 2012-11-22 | — | — | US | disclosed |
| US-20120296101-A1 | PROCESS FOR THE PREPARATION OF DARUNAVIR AND DARUNAVIR INTERMEDIATES | MAPI PHARMA LIMITED (IL) | 2012-11-22 | — | — | US | disclosed |
| WO-2011092687-A1 | PROCESS FOR THE PREPARATION OF DARUNAVIR AND DARUNAVIR INTERMEDIATES | MAPI PHARMA HK LIMITED (CN) | 2011-08-04 | — | — | WO | disclosed |
| EP-1029856-B1 | PROCESS FOR THE PREPARATION OF (2R, 3S)-3-AMINO-1,2-OXIRANE | KANEKA CORP (JP) | 2004-06-16 | — | — | EP | disclosed |
| US-6348615-B2 | CHEMICAL INTERMEDIATES FOR PROTEASE INHIBITORS | KANEKA CORPORATION (JP) | 2002-02-19 | — | — | US | disclosed |
| US-20010018532-A1 | Chemical intermediates for protease inhibitors | KANEKA CORPORATION | 2001-08-30 | — | — | US | disclosed |
| US-6278002-B1 | TREATOMG (2S,3S)-3-AMINO-1-HALO-2-HYDROXY-4-PHENYLBUTANE OR (2S,3S)-3-AMINO-4-PHENYLBUTANE-1,2-EPOXIDE WITH CARBOXYLIC ACID QUATERNARY AMMNOIUM SALT OR CARBOXYLIC ACID METAL SALT OR QUATERNARY AMMNOIUM SALT; TREATING WITH SULFONIC ACID HALIDE | KANEKA CORPORATION (JP) | 2001-08-21 | — | — | US | disclosed |
| EP-1029856-A1 | PROCESS FOR THE PREPARATION OF (2R, 3S)-3-AMINO-1,2-OXIRANE | Kaneka Corporation (JP) | 2000-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144461-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | SAMHD1, CYP3A5, DARS1 | EPHX1 3938/4885CSNK1E 856/4885SLC15A1 3233/4885 |
| US-10544157-B2 | Process for preparation of Darunavir | SAMHD1, CYP3A5, DARS1 | EPHX1 3938/4885CSNK1E 856/4885SLC15A1 3233/4885 |
| US-20150203506-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | SAMHD1, DARS1, CYP3A43 | EPHX1 4112/4885CSNK1E 861/4885SLC15A1 3768/4885 |
| US-20160355525-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | SAMHD1, CYP3A5, DARS1 | EPHX1 3938/4885CSNK1E 856/4885SLC15A1 3233/4885 |
| US-20010018532-A1 | Chemical intermediates for protease inhibitors | DNPEP, PRSS1, PREP | EPHX1 646/4885CSNK1E 803/4885SLC15A1 2419/4885 |
| US-20120296101-A1 | PROCESS FOR THE PREPARATION OF DARUNAVIR AND DARUNAVIR INTERMEDIATES | CYP3A43, CYP3A4, DHPS | EPHX1 1734/4885CSNK1E 1321/4885SLC15A1 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.